COVID-19

touchREVIEWS in Neurology. 2021;17(1):53-5 DOI: https://doi.org/10.17925/USN.2021.17.1.53

touchNEUROLOGY were delighted to have the opportunity to speak with Amos Korczyn, Founder and President of CONy about his highlights of this year’s virtual meeting.

European Neurological Review. 2020;15(1):9-10 DOI: https://doi.org/10.17925/ENR.2020.15.1.9  

Professor Emeritus of Addiction Medicine, Hannu Alho (University of Helsinki, Finland) discusses the need for effective treatment options to manage alcohol use disorder, focusing on odansetron as a newly emerging possibility. Ondansetron is a specific 5HT3-receptor antagonist, which blocks 5HT3 receptors in the gastrointestinal tract and central nervous system, and has been used since the early 90s as an effective antiemetic in the prevention of chemo- and radiotherapy-induced nausea and vomiting. Here, Prof. Alho considers the rationale for its use in alcohol use disorder, the genetic segmentation approach, design and clinical data so far from the currently recruiting ONWARD study (ClinicalTrials.gov Identifier: NCT04101227), and how this potential therapy could fit into clinical practice.

European Neurological Review. 2020;15(1):13-7 DOI: https://doi.org/10.17925/ENR.2020.15.1.13  

Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including his perspective on the COVID-19 pandemic as a Swedish geriatric neurologist.

Great to catch-up with Andrew Chan (Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland), who discussed challenges posed to patient care by COVID-19, factors to consider around immunosuppression for patients with multiple sclerosis (MS) during the pandemic, as well his personal thoughts on exciting developments in MS therapy and the 1st Virtual EAN Congress.

We caught up with our Editorial Board member, Angelo Antonini (University of Padova, Veneto, Italy), to discuss the neurological and psychiatric events that have been observed in patients with COVID-19, what could be done to prepare for these and if anything can be learnt from current experience.

So pleased to have had an opportunity to catch-up with editorial board member, K Ray Chaudhuri (King’s Parkinson’s Centre, King’s College Hospital and Kings College London, UK), who shared his expert perspective on the clinical impact of COVID-19 on people with Parkinson’s disease.

So pleased to have had an opportunity to catch-up with editorial board member, K Ray Chaudhuri (King’s Parkinson’s Centre, King’s College Hospital and Kings College London, UK), who shared his expert perspective on the clinical impact of COVID-19 on people with Parkinson’s disease.

A pleasure speaking to editorial board member, Joaquim Ferreira (Faculty of Medicine, University of Lisbon, and Campus Neurológico Sénior, Torres Vedras, Portugal), as always! He shared his personal thoughts in these uncertain times on the likely long-lasting impact of COVID-19.

A pleasure speaking to editorial board member, Joaquim Ferreira (Faculty of Medicine, University of Lisbon, and Campus Neurológico Sénior, Torres Vedras, Portugal), as always! He shared his personal thoughts in these uncertain times on the likely long-lasting impact of COVID-19.

As a coordinating member of the EANcore COVID-19 initiative, Elena Moro (Centre Hospitalier Universitaire de Grenoble, France), discusses the importance of the EAN’s recently completed survey of neurological symptoms in patients with COVID-19.

EAN Treasurer, Elena Moro (Centre Hospitalier Universitaire de Grenoble, France), kindly took the time to share with us her expert perspective on the neurological implications of COVID-19 in Europe.

EAN Acting President, Prof. Claudio Bassetti (Inselspital, Bern University Hospital, University of Bern, Switzerland), talks to us about the recently launched EANcore COVID-19 initiatives, providing valuable resources in the ongoing global crisis.

Professor Helen Cross OBE is a globally-recognised authority on Dravet Syndrome and Chair of DSUK’s Medical Advisory Board. On Monday 30 March, she took part in a webinar for families registered with DSUK, presenting on COVID-19 and answering a range of questions.

Considering the impact COVID-19 could have on those with multiple sclerosis, we were delighted to speak with Dr Asaff Harel (Lennox Hill Hospital, New York, NY, USA) on the subject.

This is a video recording of a Facebook Live Q&A that took place on March 23, 2020 with APDA’s Leslie Chambers and Dr. Rebecca Gilbert sharing answers to questions and concerns about COVID-19 and the Parkinson’s community.

Professor Huali Wang, Executive Vice President of ADI’s member association in China, Alzheimer’s Disease Chinese (ADC), explains how China has addressed the specific challenges of people living with dementia during the COVID-19 outbreak, and how this advice can be used in other countries across the world.

touchNEUROLOGY met with Robert Shapiro (Larner College of Medicine at the University of Vermont, Burlington, VT, USA) to discuss the impact of COVID-19 on individuals with migraine.

touchNEUROLOGY met with Robert Shapiro (Larner College of Medicine at the University of Vermont, Burlington, VT, USA) to discuss the impact of COVID-19 on individuals with migraine.

touchNEUROLOGY had the pleasure of meeting with Amy Gelfand (University of California, San Francisco, CA, USA) to discuss what is known about the impact of preventative migraine medication on the COVID-19 vaccine.